EORTC-24051-HNCG

Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell.
Trial StatusAll trial activities ended
DatesDate of activation: 09-May-07
Closed on : 04-Nov-08
Data management at EORTCFull
Phase1-2
Randomized trial
Type-
Targeted Sample sizeEORTC Groups: - - All Groups: 127
Number of steps1
DrugFluorouracil
Carboplatin
Cisplatin
Docetaxel
Lapatinib
Study StaffAhmad Awada
Study Coordinator - Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels
Jan Bogaerts
Statistician - EORTC Headquarters, Brussels
Denis Lacombe
Coordinating Physician - , Bremen
Denis Lacombe
Coordinating Physician - EORTC Headquarters, Brussels
Denis Lacombe
Coordinating Physician - , Bremen
Type of cancerHead and Neck
Participating GroupsEORTC Head and Neck Cancer Group(Coordinating Group)
Protocol summaryClinicalTrials.gov
NCT numberNCT00498953
EudraCT2006-002667-33